Drug
Lci699
Lci699: highest development phase Phase 2, developed by Recordati. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Recordati
Trials
| Drug | Phase | Indication |
|---|---|---|
| LCI699 NCT03708900 | Phase 2 | Cushing Syndrome |
Latest
No recent events.
Follow Lci699 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.